RFK Jr, HHS & MAHA

  • Thread starter Thread starter nycfan
  • Start date Start date
  • Replies: 2K
  • Views: 75K
  • Politics 

“… Moderna launched a global randomized controlled trial in September 2024 with 41,000 participants, half of whom received its vaccine. The other half received a standard flu vaccine as a control. The FDA blessed its trial design, and agency staffers gave Moderna a thumbs up to apply for approval last August based on the results. Its vaccine was 27% more effective at preventing symptomatic cases of flu and 49% more effective against hospitalization than the standard flu vaccine.

Yet Dr. Prasad said Moderna should have used a high-dose flu vaccine as its control rather than a standard dose—though that wasn’t possible. In the U.S., high-dose flu vaccines are typically given only to seniors over age 65. They aren’t available in many European countries where Moderna conducted its trial. That’s in part because government-run health systems don’t want to pay for expensive high-dose vaccines. Irony alert: Dr. Prasad is a fan of single-payer healthcare.

Even so, Moderna’s vaccine proved equally effective as high-dose shots in a side-by-side comparison with a standard dose. One advantage of Moderna’s mRNA vaccines, however, is that they can be quickly adapted and manufactured to match new strains….”
 
Back
Top